Mr Jessie Cacho, in Mchenry, IL - Licensed Vocational Nurse

Mr Jessie Cacho, is a Licensed Vocational Nurse based in Mchenry, Illinois. Mr Jessie Cacho is licensed to practice in Illinois (license number 043106986) and his current practice location is 3715 Municipal Dr, Mchenry, Illinois. He can be reached at his office (for appointments etc.) via phone at (847) 688-1900.

NPI number for Mr Jessie Cacho is 1326748450 and his current mailing address is 3001 Green Bay Rd, North Chicago, Illinois. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1326748450.

Contact Information

	Mr Jessie Cacho,
	3715 Municipal Dr, Mchenry, IL 60050-5483
	(847) 688-1900
	Not Available

Provider's Profile

Full Name	Mr Jessie Cacho
Gender	Male
Speciality	Licensed Vocational Nurse
Location	3715 Municipal Dr, Mchenry, Illinois
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1326748450
Provider Enumeration Date: 03/07/2023
Last Update Date: 03/07/2023

Medical Identifiers

Medical identifiers for Mr Jessie Cacho such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1326748450	NPI	-	NPPES
043106986	Other	IL	IFDPR

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
164X00000X	Licensed Vocational Nurse	043106986 (Illinois)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Mr Jessie Cacho is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Mr Jessie Cacho, 3001 Green Bay Rd, North Chicago, IL 60064-3048 Ph: (847) 688-1900	Mr Jessie Cacho, 3715 Municipal Dr, Mchenry, IL 60050-5483 Ph: (847) 688-1900

News Archive

FDA Advisory Committee recommends marketing approval for Auxilium's XIAFLEX to treat Dupuytren's contracture

Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the Arthritis Advisory Committee appointed by the U.S. Food and Drug Administration (FDA) recommended by a unanimous vote of 12 to 0 that XIAFLEX™ (collagenase clostridium histolyticum), a novel, first-in-class, orphan-designated, biologic, be granted marketing approval by the FDA for the treatment of Dupuytren's contracture.

SANUWAVE receives U.S. patent titled, 'Device for the Application of Acoustic Shock Waves'

SANUWAVE Health, Inc., an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, today announced that the U.S. Patent and Trademark Office (USPTO) has issued the Company patent number 8,088,073, titled "Device for the Application of Acoustic Shock Waves."

Low baseline QOL scores does not predict worse survival in patients undergoing lung cancer surgery

Quality of life (QOL) is rarely reported in surgical publications, yet it can be an important metric that can be of use to physicians and patients when making treatment decisions.

TGen to lead multidisciplinary search for new drugs that could help treat GBM

The Translational Genomics Research Institute (TGen) will lead a multidisciplinary search for new drugs that could help treat the most common and lethal form of brain cancer.

New data supports safety of ranolazine but not its effectiveness

The anti-anginal medication ranolazine was shown to be safe in regard to certain outcomes but did not reduce the risk of major cardiovascular events such as death, heart attack or recurrent ischemia following acute coronary syndromes, according to a study in the April 25 issue of JAMA .

Mr Jessie Cacho, - Licensed Vocational Nurse in Mchenry, IL